JP2023509968A5 - - Google Patents
Info
- Publication number
- JP2023509968A5 JP2023509968A5 JP2022542216A JP2022542216A JP2023509968A5 JP 2023509968 A5 JP2023509968 A5 JP 2023509968A5 JP 2022542216 A JP2022542216 A JP 2022542216A JP 2022542216 A JP2022542216 A JP 2022542216A JP 2023509968 A5 JP2023509968 A5 JP 2023509968A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- human subject
- inhibitor
- malignant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025186533A JP2026027353A (ja) | 2020-01-08 | 2025-11-05 | 脾腫を治療する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062958632P | 2020-01-08 | 2020-01-08 | |
| US62/958,632 | 2020-01-08 | ||
| PCT/US2021/012696 WO2021142257A1 (en) | 2020-01-08 | 2021-01-08 | Methods of treating splenomegaly |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025186533A Division JP2026027353A (ja) | 2020-01-08 | 2025-11-05 | 脾腫を治療する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023509968A JP2023509968A (ja) | 2023-03-10 |
| JP2023509968A5 true JP2023509968A5 (cg-RX-API-DMAC10.html) | 2024-01-17 |
| JP7771064B2 JP7771064B2 (ja) | 2025-11-17 |
Family
ID=76788747
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022542216A Active JP7771064B2 (ja) | 2020-01-08 | 2021-01-08 | 脾腫を治療する方法 |
| JP2025186533A Pending JP2026027353A (ja) | 2020-01-08 | 2025-11-05 | 脾腫を治療する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025186533A Pending JP2026027353A (ja) | 2020-01-08 | 2025-11-05 | 脾腫を治療する方法 |
Country Status (15)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12662484B2 (en) | 2016-08-17 | 2026-06-23 | Shenzhen Targetrx, Inc. | Substituted piperidines as bruton's tyrosine kinase inhibitors |
| WO2021142257A1 (en) * | 2020-01-08 | 2021-07-15 | Telios Pharma, Inc. | Methods of treating splenomegaly |
| US12697333B2 (en) | 2020-01-08 | 2026-08-04 | Telios Pharma, Inc. | Methods of treating splenomegaly |
| WO2022266285A1 (en) * | 2021-06-16 | 2022-12-22 | Telios Pharma Inc. | Treatment of symptoms associated with myeloproliferative neoplasms |
| WO2023071973A1 (en) * | 2021-10-26 | 2023-05-04 | Shenzhen Targetrx, Inc. | Fused bicyclic compound for inhibiting activity of tyrosine kinase |
| JP2025527431A (ja) * | 2022-08-25 | 2025-08-22 | ビーワン メディシンズ ワン ゲーエムベーハー | （ｓ）－７－（１－アクリロイルピペリジン－４－イル）－２－（４－フェノキシフェニル）－４，５，６，７－テトラヒドロピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミド及びシュウ酸を含む固体形態、その組成物及び使用方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015057992A1 (en) * | 2013-10-16 | 2015-04-23 | Izumi Raquel | Btk inhibitors for hematopoietic mobilization |
| WO2015081127A2 (en) * | 2013-11-26 | 2015-06-04 | Gilead Sciences, Inc. | Therapies for treating myeloproliferative disorders |
| SMT202100674T1 (it) * | 2014-08-11 | 2022-01-10 | Acerta Pharma Bv | Combinazioni terapeutiche di un inibitore di btk e un inibitore di bcl-2 |
| WO2016054491A1 (en) * | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EP3810590A1 (en) * | 2018-06-19 | 2021-04-28 | Merck Patent GmbH | Novel crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, salt forms thereof, and processes to obtain |
| CN109942835A (zh) * | 2019-03-27 | 2019-06-28 | 广州楹鼎生物科技有限公司 | 一种催化分解木质纤维原料的方法 |
| TW202128156A (zh) * | 2019-11-14 | 2021-08-01 | 美商夸格智財控股有限公司 | 用於癌症治療之btk抑制劑及mdm2抑制劑之組合 |
| WO2021142257A1 (en) * | 2020-01-08 | 2021-07-15 | Telios Pharma, Inc. | Methods of treating splenomegaly |
-
2021
- 2021-01-08 WO PCT/US2021/012696 patent/WO2021142257A1/en not_active Ceased
- 2021-01-08 CR CR20220374A patent/CR20220374A/es unknown
- 2021-01-08 TN TNP/2022/000185A patent/TN2022000185A1/en unknown
- 2021-01-08 BR BR112022013646A patent/BR112022013646A2/pt unknown
- 2021-01-08 KR KR1020227027305A patent/KR20220130151A/ko active Pending
- 2021-01-08 CA CA3164063A patent/CA3164063A1/en active Pending
- 2021-01-08 MA MA63848A patent/MA63848B1/fr unknown
- 2021-01-08 EP EP21738476.7A patent/EP3980069A4/en active Pending
- 2021-01-08 MX MX2022008490A patent/MX2022008490A/es unknown
- 2021-01-08 AU AU2021205484A patent/AU2021205484A1/en active Pending
- 2021-01-08 EP EP22150344.4A patent/EP4000624A1/en active Pending
- 2021-01-08 MA MA57226A patent/MA57226B1/fr unknown
- 2021-01-08 IL IL294582A patent/IL294582A/en unknown
- 2021-01-08 JP JP2022542216A patent/JP7771064B2/ja active Active
- 2021-01-08 MA MA69153A patent/MA69153A1/fr unknown
- 2021-01-08 CN CN202180004918.1A patent/CN114423457A/zh active Pending
-
2022
- 2022-07-07 JO JOP/2022/0168A patent/JOP20220168A1/ar unknown
- 2022-07-28 CO CONC2022/0010592A patent/CO2022010592A2/es unknown
-
2025
- 2025-11-05 JP JP2025186533A patent/JP2026027353A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL294582A (en) | Methods for treating an enlarged spleen | |
| JP6364546B2 (ja) | 抗腫瘍剤の副作用軽減剤 | |
| JP2025176093A5 (cg-RX-API-DMAC10.html) | ||
| CN1350454A (zh) | 阿朴吗啡和西地拉非组合物 | |
| JPH02240021A (ja) | 抑うつ障害の治療用に適した制御放出製薬組成物 | |
| JP2021523220A5 (cg-RX-API-DMAC10.html) | ||
| EA037152B1 (ru) | Способ лечения рака | |
| US12544370B2 (en) | Methods for cancer therapy | |
| EP2076266A2 (en) | Method of treating inflammatory diseases using tyroskine kinase inhibitors | |
| CN114681455A (zh) | 组蛋白去乙酰化酶抑制剂与蛋白激酶抑制剂之组合及其制药用途 | |
| CN102647986A (zh) | 治疗增殖性障碍和其它由bcr-abl、c-kit、ddr1、ddr2或pdgf-r激酶活性介导的病理学病症的方法 | |
| JP2006528229A (ja) | Ｐｄｅ４阻害剤及びｐｄｅ５阻害剤を含有する組成物 | |
| JP2025507830A5 (cg-RX-API-DMAC10.html) | ||
| CN118593502A (zh) | 一种预防或治疗tp53突变双打击淋巴瘤的联合用药物组合物及其应用 | |
| TW202011948A (zh) | 接受造血幹細胞移植的患者之血液惡性腫瘤的復發抑制劑 | |
| CA2672716C (fr) | Nouvelle utilisation therapeutique pour le traitement des leucemies | |
| RU2003332C1 (ru) | Средство дл лечени депрессий | |
| JP2002539247A (ja) | マンズアミンの抗炎症作用の使用 | |
| JPH01153665A (ja) | 免疫転形及び細胞増殖抑制のためのジヒドロフェニルアミノ酸誘導体の使用及びそれを含む薬学組成物 | |
| BR112020016389A2 (pt) | Uso de 5-fluor-4-(4-fluor-2-metoxifenil)-n-{4-[(s-metilsulfonimidoil)metil]piridin-2-il}piridin-2-amina para tratamento de linfoma difuso de células b grandes | |
| EP4225316A1 (en) | Use of an erk inhibitor for the treatment of myelofibrosis | |
| RU2519199C2 (ru) | Противоопухолевый агент, набор и способ лечения рака | |
| CN113274394A (zh) | 一种治疗酪氨酸激酶抑制剂耐药的非小细胞肺癌的药物组合物 | |
| EP4225317A1 (en) | Use of an erk inhibitor for the treatment of myelofibrosis | |
| MXPA06014477A (es) | Agente antitumor, fortificador de efecto antitumor y metodo de terapia para cancer. |